Figure 3.

Prognosis of patients in responder and non-responder groups based on PT and LN responses to NAC. Comparison of DFS between patients in the responder and non-responder groups according to (A) PT and (B) LN responses to NAC. Comparison of OS between patients in the responder and non-responder groups according to (C) PT and (D) LN responses to NAC. OS and DFS were estimated using the Kaplan-Meier method using a weighted test. PT, primary tumor site; LN, lymph node; NAC, neoadjuvant chemotherapy; DFS, disease-free survival; OS, overall survival.